Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,597 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.5
Industry P/E
--
EV/EBITDA
-2.7
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$6.3
EPS
$-2.2
Face value
--
Shares outstanding
57,510,635
CFO
$-108.12 Mln
EBITDA
$-159.26 Mln
Net Profit
$-142.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
| 11.3 | 15.0 | 11.3 | 238.9 | 96.7 | 46.1 | 2.1 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
| 109.1 | 179.8 | 26.7 | 31.7 | -14.6 | 168.0 | -68.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Capricor Therapeutics (CAPR)
|
32.1 | 1,597.1 | 0.0 | -105.0 | -- | -46.6 | -- | 5.5 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the... United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California. Address: 10865 Road to the Cure, San Diego, CA, United States, 92121 Read more
Executive Chairman of the Board
Dr. Frank Isaac Litvack FACC, M.D.
Executive Chairman of the Board
Dr. Frank Isaac Litvack FACC, M.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Capricor Therapeutics Inc (CAPR) is $32.11 (NASDAQ) as of 02-Apr-2026 17:41 EDT. Capricor Therapeutics Inc (CAPR) has given a return of 96.69% in the last 3 years.
Since, TTM earnings of Capricor Therapeutics Inc (CAPR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-13.42
|
4.61
|
|
2024
|
-12.01
|
3.34
|
|
2023
|
-5.88
|
5.79
|
|
2022
|
-3.35
|
8.24
|
|
2021
|
-3.53
|
2.26
|
The 52-week high and low of Capricor Therapeutics Inc (CAPR) are Rs 40.37 and Rs 4.30 as of 05-Apr-2026.
Capricor Therapeutics Inc (CAPR) has a market capitalisation of $ 1,597 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Capricor Therapeutics Inc (CAPR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$1.99
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.